Stay updated with the latest stock market news and insights
Weekly insights + SMS alerts
Imagine being a doctor and getting back 200,000 hours of your life. That's not a fantasy—it's what Oracle Corp. (ORCL) says its new AI tool has done for physicians across the U.S. And investors are loving it.
The software giant's shares surged Wednesday after it delivered a classic one-two punch: better-than-expected quarterly results and a genuinely interesting product announcement that shows AI isn't just hype—it's actually saving people time.
On Tuesday, Oracle reported third-quarter revenue of $17.19 billion. That beat the $16.91 billion analysts were expecting. Even better, adjusted earnings grew 21% year-over-year to $1.79 per share, topping estimates of $1.71.
Looking ahead, the company expects fourth-quarter revenue to grow 18% to 20% on a year-over-year basis, roughly in line with what the Street was anticipating. It sees adjusted earnings per share landing between $1.96 and $2.00 for the quarter, versus estimates of $1.95.
In other words: solid beat now, confident guidance for later. That's the kind of report that gets analysts reaching for their rating models.
Separately—and this is the really cool part—Oracle announced that its Oracle Health Clinical AI Agent for automated note generation is now available in U.S. emergency departments and inpatient settings.
Here's how it works: The tool listens to real-time patient interactions and pulls data from the electronic health record—things like triage notes, lab results, and imaging info. Then it automatically drafts a clinical note. The doctor reviews it, makes any edits, and finalizes it. No more staring at a screen for hours after a long shift.
Healthcare systems are already seeing results. AtlantiCare, for instance, expanded the tool across its emergency departments after earlier deployments cut documentation time by 41%.
"Just as we saw in our ambulatory settings, we're now seeing that same impact in the emergency department," said Jordan Ruch, chief information officer at AtlantiCare.
And the big number? Oracle says the AI system has saved physicians more than 200,000 hours across U.S. providers since launching just over a year ago. That's time doctors can spend with patients instead of paperwork.
From a technical perspective, the stock is currently trading 8.5% above its 20-day simple moving average but is 2.3% below its 50-day SMA. That suggests some short-term strength while facing resistance at that 50-day level. Over the past year, shares are up 16.38% and are trading closer to their 52-week highs than lows.
The RSI sits at 42.87, which is neutral territory—not overbought, not oversold. The MACD shows a value of -4.5644 with a signal line at -6.1777, indicating a bullish crossover. Translation: there's room for the momentum to continue.
Oracle is expected to provide its next financial update on June 10, 2026. The current consensus estimates are for EPS of $1.64 (down from $1.70) and revenue of $16.90 billion (up from $15.90 billion). The stock trades at a P/E of 28.1x, which indicates a premium valuation.
The analyst consensus is a Buy rating with an average price target of $251.64. Recent moves include:
Because of its size, Oracle is a major holding in several exchange-traded funds. This matters because big flows into or out of these ETFs can force automatic buying or selling of the stock. The key ones are:
When these ETFs get new money, they have to buy more Oracle. When investors pull money out, they have to sell. It's a mechanical relationship that can add extra juice to the stock's moves.
Oracle shares were up 8.72% at $162.43 on Wednesday. Sometimes a good earnings report is just a good earnings report. But when you pair it with a product that gives doctors back their time, it starts to look like a company that's executing on both the financial and innovation fronts.
Real-time alerts on price moves, news, and trading opportunities.
Join 20,000+ investors. No spam, ever.
